Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Syngene International Limited

Syngene International Limited is an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply. It provides customized end-to-end solutions to fulfill R&D and manufacturing requirements.

	Mar '15	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
net income	629M -	773M 22.89%	667M 13.71%	1.04B 55.92%	1.48B 42.12%	739M 50%	1.02B 38.02%	1.10B 7.55%	1.79B 62.90%	934M 47.73%	1.17B 24.73%	1.11B 4.29%	1.89B 69.15%	757M 59.86%
depreciation and amortization	224M -						902M -	946M 4.88%	956M 1.06%	1.02B 6.80%	1.05B 2.45%	1.08B 3.35%
deferred income tax	-127M -
stock based compensation	21M -				371M -
change in working capital	1.24B -
accounts receivables
inventory	-33M -
accounts payables
other working capital	1.27B -
other non cash items	-32M -	-773M 2,315.63%	-667M 13.71%	-1.04B 55.92%	-1.85B 77.79%	-739M 60.03%	-118M 84.03%	-151M 27.97%	-831M 450.33%	87M 110.47%	-119M 236.78%	-34M 71.43%	-1.89B 5,447.06%	-757M 59.86%
net cash provided by operating activities	1.96B -						1.80B -	1.89B 4.88%	1.91B 1.06%	2.04B 6.80%	2.09B 2.45%	2.16B 3.35%
investments in property plant and equipment	-688M -
acquisitions net	8M -
purchases of investments	-2.49B -
sales maturities of investments	1.29B -
other investing activites	10M -
net cash used for investing activites	-1.87B -
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites
net cash used provided by financing activities	-291M -
effect of forex changes on cash	-22M -
net change in cash	-230M -						-2.13B -	116M 105.45%	-813M 800.86%	1.70B 309.10%	-912M 153.65%	-569M 37.61%
cash at beginning of period	1.39B -						3.72B -	1.59B 57.20%	1.71B 7.29%	895M 47.60%	2.60B 189.94%	1.68B 35.14%
cash at end of period	1.16B -						1.59B -	1.71B 7.29%	895M 47.60%	2.60B 189.94%	1.68B 35.14%	1.11B 33.81%
operating cash flow	1.96B -						1.80B -	1.89B 4.88%	1.91B 1.06%	2.04B 6.80%	2.09B 2.45%	2.16B 3.35%
capital expenditure	-688M -
free cash flow	1.27B -						1.80B -	1.89B 4.88%	1.91B 1.06%	2.04B 6.80%	2.09B 2.45%	2.16B 3.35%

COM:SYNGENEINTL

Syngene International Limited

Last Close

869.30

25/11 08:30

Market Cap

295.33B

Beta: -

Volume Today

343.27K

Avg: -

Preview